In terms of next steps, of course we will look forward to a presentation of the full dataset at a scientific meeting later this year, which we expect to include the current (indiscernible) specific details on progression-free survival and objective response rate. In the meantime, we intend to evaluate the necessary next development and regulatory steps for the combination of ZYBRESTAT plus Avastin.
They probably do not have enough events yet to calculate O/S. From disease progression to death could take at least several months. So I would not expect O/S data until later in the year. The longer we wait might mean good results though not guaranteed. In any case, I would expect talks with EU regulators to be mainly based on the great progression free survival number we just received since other companies have been approved on such data.
If a large pharma wants to get a bargain price for an acquisition or partnership, they will make a move before O/S data is announced.
agreed; the fact they don't have enough events to calculate o/s is great news for the patients who are still living and us as o/s is a key indicator; what got my attention was i believe baxter specifically said no significant difference in o/s was noted. oxgn said they would continue to monitor os
do you know what the standard o/s is for the ovarian cancer oxgn is working on? i checked several tables and couldn't figure it out